These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 2239806)

  • 21. Mitoxantrone, etoposide and intermediate-dose Ara-C (MEC): an effective regimen for poor risk acute myeloid leukemia.
    Spadea A; Petti MC; Fazi P; Vegna ML; Arcese W; Avvisati G; Aloe Spiriti MA; Latagliata R; Meloni G; Testi AM
    Leukemia; 1993 Apr; 7(4):549-52. PubMed ID: 8464233
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MEC (mitoxantrone, etoposide and intermediate dose cytarabine): an effective induction regimen for previously untreated acute non-lymphocytic leukemia.
    Visani G; Petti MC; Cenacchi A; Manfroi S; Tosi P; Spadea A; Latagliata R; Amadori S; Mandelli F; Tura S
    Leuk Lymphoma; 1995 Nov; 19(5-6):447-51. PubMed ID: 8590845
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar).
    Advani R; Saba HI; Tallman MS; Rowe JM; Wiernik PH; Ramek J; Dugan K; Lum B; Villena J; Davis E; Paietta E; Litchman M; Sikic BI; Greenberg PL
    Blood; 1999 Feb; 93(3):787-95. PubMed ID: 9920827
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of poor prognosis AML patients using PSC833 (valspodar) plus mitoxantrone, etoposide, and cytarabine (PSC-MEC).
    Advani R; Visani G; Milligan D; Saba H; Tallman M; Rowe JM; Wiernik PH; Ramek J; Dugan K; Lum B; Villena J; Davis E; Paietta E; Litchman M; Covelli A; Sikic B; Greenberg P
    Adv Exp Med Biol; 1999; 457():47-56. PubMed ID: 10500779
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I/II study of clofarabine, etoposide, and mitoxantrone in patients with refractory or relapsed acute leukemia.
    Abbi KK; Rybka W; Ehmann WC; Claxton DF
    Clin Lymphoma Myeloma Leuk; 2015 Jan; 15(1):41-6. PubMed ID: 25085441
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of refractory acute myeloid leukemia with mAMSA and VP 16-213 in combination: results of a clinical phase I/II study.
    Hiddemann W; Urbanitz D; Preusser P; Achterrath W; Büchner T
    Hematol Oncol; 1989; 7(4):267-73. PubMed ID: 2737607
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mitoxantrone in the treatment of relapsed and refractory acute leukemia.
    Moore JO; Olsen GA
    Semin Oncol; 1984 Sep; 11(3 Suppl 1):41-6. PubMed ID: 6385265
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Continuous infusion intermediate-dose cytarabine, mitoxantrone, plus etoposide for refractory or early relapsed acute myelogenous leukemia.
    Lee JH; Choi SJ; Lee JH; Lee YS; Seol M; Ryu SG; Jang S; Park CJ; Chi HS; Lee JS; Kim WK; Lee KH
    Leuk Res; 2006 Feb; 30(2):204-10. PubMed ID: 16055185
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of etoposide and mitoxantrone in patients with acute myelogenous leukemia refractory to standard induction therapy and intermediate-dose cytarabine with amsidine. Dutch Hematology-Oncology Working Group for Adults (HOVON).
    Daenen S; Löwenberg B; Sonneveld P; van Putten WL; Verhoef G; Verdonck LF; van Veldhoven M; Huijgens PC
    Leukemia; 1994 Jan; 8(1):6-10. PubMed ID: 8289499
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mitoxantrone for refractory and relapsed acute leukemia.
    Bezwoda WR; Bernasconi C; Hutchinson RM; Winfield DA; de Bock R; Mandelli F
    Cancer; 1990 Aug; 66(3):418-22. PubMed ID: 2194640
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia.
    Feldman EJ; Alberts DS; Arlin Z; Ahmed T; Mittelman A; Baskind P; Peng YM; Baier M; Plezia P
    J Clin Oncol; 1993 Oct; 11(10):2002-9. PubMed ID: 8410125
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combination of mitoxantrone and etoposide in the treatment of myelodysplastic syndromes transformed into acute myeloid leukemia.
    Knauf WU; Berdel WE; Ho AD; Kreuser ED; Thiel E
    Leuk Lymphoma; 1994 Feb; 12(5-6):421-5. PubMed ID: 8180605
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The rationale of therapy with mitoxantrone in non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Co-operative Study Group, (NHLCSG) Italy.
    Chisesi T
    Leuk Lymphoma; 1993 Jan; 9(1-2):63-9. PubMed ID: 8477203
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of relapsed and refractory acute myeloid leukemia with diaziquone and mitoxantrone: a CALGB phase I study.
    Amrein PC; Davis RB; Mayer RJ; Schiffer CA
    Am J Hematol; 1990 Oct; 35(2):80-3. PubMed ID: 2399909
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Idarubicin in combination with intermediate-dose cytarabine and VP-16 in the treatment of refractory or rapidly relapsed patients with acute myeloid leukemia. The GIMEMA Cooperative Group.
    Carella AM; Carlier P; Pungolino E; Resegotti L; Liso V; Stasi R; Montillo M; Iacopino P; Mirto S; Pagano L
    Leukemia; 1993 Feb; 7(2):196-9. PubMed ID: 8426473
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Successful treatment of adult acute lymphoblastic leukemia after relapse with prednisone, intermediate-dose cytarabine, mitoxantrone, and etoposide (PAME) chemotherapy.
    Milpied N; Gisselbrecht C; Harousseau JL; Sebban C; Witz F; Troussard X; Gratecos N; Michallet M; LeBlond V; Auzanneau G
    Cancer; 1990 Aug; 66(4):627-31. PubMed ID: 2386891
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I trial of sequential topotecan followed by etoposide in adults with myeloid leukemia: a National Cancer Institute of Canada Clinical Trials Group Study.
    Crump M; Lipton J; Hedley D; Sutton D; Shepherd F; Minden M; Stewart K; Beare S; Eisenhauer E
    Leukemia; 1999 Mar; 13(3):343-7. PubMed ID: 10086724
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination therapy with mitoxantrone and etoposide in refractory acute myelogenous leukemia.
    Ho AD; Lipp T; Ehninger G; Meyer P; Freund M; Hunstein W
    Cancer Treat Rep; 1986 Aug; 70(8):1025-7. PubMed ID: 3460698
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A new combination of carboplatin, high-dose cytarabine and cross-over mitoxantrone or idarubicin for refractory and relapsed acute myeloid leukemia.
    Bassan R; Lerede T; Buelli M; Borleri G; Bellavita P; Rambaldi A; Barbui T
    Haematologica; 1998 May; 83(5):422-7. PubMed ID: 9658726
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I study of valspodar (PSC-833) with mitoxantrone and etoposide in refractory and relapsed pediatric acute leukemia: a report from the Children's Oncology Group.
    O'Brien MM; Lacayo NJ; Lum BL; Kshirsagar S; Buck S; Ravindranath Y; Bernstein M; Weinstein H; Chang MN; Arceci RJ; Sikic BI; Dahl GV
    Pediatr Blood Cancer; 2010 May; 54(5):694-702. PubMed ID: 20209646
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.